Pozen's $25 million Vimovo milestone to fund integrated aspirin portfolio
This article was originally published in Scrip
Executive Summary
Pozen says that the $25 million milestone payment that it recently received from AstraZeneca following marketing and pricing approval for Vimovo (naproxen/ esomeprazole magnesium) in the UK will fund the development of its integrated aspirin therapies, which it refers to as its PA pipeline.